Kaharu Sumino1,2, Emily R Locke3, Sheryl Magzamen4, Ina Gylys-Colwell3, Olivier Humblet5, Huong Q Nguyen6, Rachel M Thomas3, Vincent S Fan3,7. 1. 1 Department of Medicine, Washington University School of Medicine , St. Louis, Missouri. 2. 2 VA Saint Louis Health System, Saint Louis VA Medical Center , St. Louis, Missouri. 3. 3 Department of Health Services Research and Development, VA Puget Sound Health Care System , Seattle, Washington. 4. 4 Environmental and Radiological Health Sciences, Colorado State University , Fort Collins, Colorado. 5. 5 Propeller Health , Madison, Wisconsin. 6. 6 Department of Research and Evaluation, Kaiser Permanente Southern California , Pasadena, California. 7. 7 Department of Medicine, University of Washington , Seattle, Washington.
Abstract
BACKGROUND: Remote inhaler monitoring is an emerging technology that enables the healthcare team to monitor the time and location of a patient's inhaler use. We assessed the feasibility of remote inhaler monitoring for chronic obstructive pulmonary disease (COPD) patients and the pattern of albuterol inhaler use associated with COPD exacerbations. METHODS: Thirty-five participants with COPD used an electronic inhaler sensor for 12 weeks which recorded the date and time of each albuterol actuation. Self-reported COPD exacerbations and healthcare utilization were assessed monthly. We used generalized estimating equations with a logit link to compare the odds of an exacerbation day to a nonexacerbation day by the frequency of daily albuterol use. RESULTS: Average daily albuterol use on nonexacerbation days varied greatly between patients, ranging from 1.5 to 17.5 puffs. There were 48 exacerbation events observed in 29 participants during the study period, of which 16 were moderate-to-severe exacerbations. During the moderate-to-severe exacerbation days, the median value in average daily albuterol use increased by 14.1% (interquartile range: 2.7%-56.9%) compared to average nonexacerbation days. A 100% increase in inhaler use was associated with increased odds of a moderate-to severe exacerbation (odds ratio 1.54; 95% CI: 1.21-1.97). Approximately 74% of participants reported satisfaction with the sensor. CONCLUSIONS: The electronic inhaler sensor was well received in older patients with COPD over a 12-week period. Increased albuterol use captured by the device was associated with self-reported episodes of moderate-to-severe exacerbations.
BACKGROUND: Remote inhaler monitoring is an emerging technology that enables the healthcare team to monitor the time and location of a patient's inhaler use. We assessed the feasibility of remote inhaler monitoring for chronic obstructive pulmonary disease (COPD) patients and the pattern of albuterol inhaler use associated with COPD exacerbations. METHODS: Thirty-five participants with COPD used an electronic inhaler sensor for 12 weeks which recorded the date and time of each albuterol actuation. Self-reported COPD exacerbations and healthcare utilization were assessed monthly. We used generalized estimating equations with a logit link to compare the odds of an exacerbation day to a nonexacerbation day by the frequency of daily albuterol use. RESULTS: Average daily albuterol use on nonexacerbation days varied greatly between patients, ranging from 1.5 to 17.5 puffs. There were 48 exacerbation events observed in 29 participants during the study period, of which 16 were moderate-to-severe exacerbations. During the moderate-to-severe exacerbation days, the median value in average daily albuterol use increased by 14.1% (interquartile range: 2.7%-56.9%) compared to average nonexacerbation days. A 100% increase in inhaler use was associated with increased odds of a moderate-to severe exacerbation (odds ratio 1.54; 95% CI: 1.21-1.97). Approximately 74% of participants reported satisfaction with the sensor. CONCLUSIONS: The electronic inhaler sensor was well received in older patients with COPD over a 12-week period. Increased albuterol use captured by the device was associated with self-reported episodes of moderate-to-severe exacerbations.
Authors: Barbara P Yawn; Gretchen M McCreary; John A Linnell; Cara B Pasquale; Elisha Malanga; Radmila Choate; David A Stempel; Rahul Gondalia; Leanne Kaye; Kathryn A Collison; Benjamin S Wu; Daniel Gratie; Richard H Stanford; Ryan Tomlinson Journal: Chronic Obstr Pulm Dis Date: 2021-10-28
Authors: Amy H Y Chan; Roy A Pleasants; Rajiv Dhand; Stephen L Tilley; Stephen A Schworer; Richard W Costello; Rajan Merchant Journal: Pulm Ther Date: 2021-08-11
Authors: Russell Bowler; Matthew Allinder; Sean Jacobson; Andrew Miller; Bruce Miller; Ruth Tal-Singer; Nicholas Locantore Journal: BMJ Open Respir Res Date: 2019-02-18
Authors: Jessica Chen; Leanne Kaye; Michael Tuffli; Meredith A Barrett; Shelanda Jones-Ford; Tina Shenouda; Rahul Gondalia; Kelly Henderson; Veronica Combs; David Van Sickle; David A Stempel Journal: JMIR Form Res Date: 2019-10-23
Authors: Gary T Ferguson; Tor Skärby; Lars H Nordenmark; Rosa Lamarca; Audrone Aksomaityte; Dan Lythgoe; Ileen Gilbert; Frank Trudo Journal: Int J Chron Obstruct Pulmon Dis Date: 2020-11-27
Authors: Gerard J Criner; Therese Cole; Kristen A Hahn; Kari Kastango; James Eudicone; Ileen Gilbert Journal: Int J Chron Obstruct Pulmon Dis Date: 2021-03-04